Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRCP | P42785 | 8/20 | 0.53 |
| ▸ | GAA | P10253 | 2/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
| ▸ | GID4 | Q8IVV7 | 1/20 | 0.47 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.47 |
| ▸ | RECQL | P46063 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | HTR2A | P28223 | 1/20 | 0.43 |
| ▸ | HTR2C | P28335 | 1/20 | 0.43 |
| ▸ | HTR2B | P41595 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL95059 | 1.00 | PRCP (0.53) | PRCPGAATSHRNPSR1GID4 | |
| SCHEMBL28967711 | 0.89 | PRCP (0.42) | PRCPGAATSHRNPSR1GID4 | |
| SCHEMBL4354734 | 0.81 | PRCP (0.56) | PRCPGAATSHRNPSR1GID4 | |
| SCHEMBL28762516 | 0.81 | PRCP (0.58) | PRCPGAATSHRNPSR1GID4 | |
| SCHEMBL27808728 | 0.81 | PRCP (0.53) | PRCPGAATSHRNPSR1GID4 | |
| SCHEMBL23285173 | 0.81 | PRCP (0.53) | PRCPGAATSHRNPSR1GID4 | |
| SCHEMBL28252983 | 0.81 | PRCP (0.53) | PRCPGAATSHRNPSR1GID4 | |
| SCHEMBL3087062 | 0.81 | CYP2D6 (0.38) | PRCPTSHRMAPTKDM4EALDH1A1 | |
| SCHEMBL30435099 | 0.81 | CYP2D6 (0.38) | PRCPTSHRMAPTKDM4EALDH1A1 | |
| SCHEMBL13281275 | 0.79 | PRCP (0.50) | PRCPGAATSHRNPSR1GID4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7951801-B2 | For therapy of inflammatory disease and cancer | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-05-31 | — | — | US | disclosed |
| EP-2206713-A1 | Beta-carbolines useful for treating inflammatory disease | Millennium Pharmaceuticals, Inc. (US) | 2010-07-14 | — | — | EP | disclosed |
| US-7727985-B2 | Beta-carbolines useful for treating inflammatory disease | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2010-06-01 | — | — | US | disclosed |
| US-20100093713-A1 | BETA-CARBOLINES USEFUL FOR TREATING INFLAMMATORY DISEASE | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2010-04-15 | — | — | US | disclosed |
| EP-1735311-B1 | BETA-CARBOLINES USEFUL FOR TREATING INFLAMMATORY DISEASE | MILLENNIUM PHARM INC (US) | 2010-03-31 | — | — | EP | disclosed |
| EP-1735311-A1 | BETA-CARBOLINES USEFUL FOR TREATING INFLAMMATORY DISEASE | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2006-12-27 | — | — | EP | disclosed |
| CN-1802375-A | Beta-carbolines useful for treating inflammatory disease | MILLENNIUM PHARM INC (US) | 2006-07-12 | — | — | CN | disclosed |
| EP-1611134-A1 | BETA-CARBOLINES USEFUL FOR TREATING INFLAMMATORY DISEASE | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2006-01-04 | — | — | EP | disclosed |
| WO-2005111037-A1 | BETA-CARBOLINES USEFUL FOR TREATING INFLAMMATORY DISEASE | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2005-11-24 | — | — | WO | disclosed |
| US-20050239781-A1 | Beta-carbolines useful for treating inflammatory disease | MILLENNIUM PHARMACEUTICALS, INC. | 2005-10-27 | — | — | US | disclosed |
| US-20040235839-A1 | Beta-carbolines useful for treating inflammatory disease | MILLENNIUM PHARMACEUTICALS, INC. | 2004-11-25 | — | — | US | disclosed |
| WO-2004092167-A1 | BETA-CARBOLINES USEFUL FOR TREATING INFLAMMATORY DISEASE | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2004-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050239781-A1 | Beta-carbolines useful for treating inflammatory disease | IL1B, IL1A, ADRA2B | PRCP 2005/4885GAA 1324/4885TSHR 2728/4885 |
| US-20040235839-A1 | Beta-carbolines useful for treating inflammatory disease | NFKBIA, IRAK2, IRAK1 | PRCP 3704/4885GAA 4494/4885TSHR 3141/4885 |
| US-20100093713-A1 | BETA-CARBOLINES USEFUL FOR TREATING INFLAMMATORY DISEASE | NFKBIA, NFKB2, IKBKG | PRCP 3596/4885GAA 4504/4885TSHR 2390/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.